MedTrace Logo

Canakinumab for Treatment of Adult-onset Still's Disease

NCT02204293 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-08-07

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.

Conditions

  • Adult-Onset Still´s Disease

Interventions

DRUG

Canakinumab

Canakinumab, single-dose 4 mg/kg up to 300 mg administered subcutaneously.

DRUG

Placebo

Matching placebo administered subcutaneously.

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Eugen Feist, Prof. Dr. · Charité University Berlin Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-21
Primary Completion
2018-05-05
Completion
2018-05-05

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02204293 on ClinicalTrials.gov